Akshay Vaishnaw

Akshay Vaishnaw is currently a Board Member at Editas Medicine. Akshay was previously the Founder of HG III Consulting from September 2018 to December 2019. There, they directed the operations of a 75 MM unit / year OTC pharmaceutical operation, managing key brands such as Robitussin, Dimetapp, Advil and Children’s Advil. Akshay was also responsible for the operational, financial, compliance, and quality performance of the factory. Some of their significant accomplishments include increasing productivity per DL operator from 500,000 units / year to 1.4 units million / year, improving Robitussin cycle time of key product line by 65 % , improving monthly released to plan metric from 75 % to 95 %, improving training curriculum completion from 67 % to 95%, directing the design, installation, and qualification of a $11 million packaging automation plan, creating a job sharing packaging technician program resulting in $2.4MM cost savings to date, and launching an average of five new SKU’s / year – all launches on schedule or early. In 2003 and 2006, the FDA inspection result was Zero FD-483 observations. Akshay was also the Site Leader of Diversity program and was a finalist for 2006 SPHR Diversity Employer All-Star Award. From July 2010 to January 2020, they were the SVP Quality and Continuous Improvement at Patheon.

Akshay Vaishnaw has a MS in Microbiology from East Tennessee State University.